分析依达拉奉+奥拉西坦治疗大面积脑梗死的疗效及对神经功能的影响

Analysis on the Efficacy of Edaravone + Oxiracetam in the Treatment of Large-area Cerebral Infarction and Its Effect on Neurological Function

目的 探讨对于大面积脑梗死患者的临床治疗中应用依达拉奉结合奥拉西坦的效果及对神经功能的影响。方法 随机选取2020年1月—2021年4月黄冈市中心医院收治的80例大面积脑梗死患者,按随机数字表法分成观察组与对照组,各40例。两组患者均采用基础方式干预,对照组在此基础上使用依达拉奉持续干预14 d,观察组则采取依达拉奉联合奥拉西坦持续干预14 d。比较两组临床疗效、神经功能(NIHSS)与日常生活能力(BI)变化、血清炎症因子(hs-CRP、TNF-α)变化以及不良反应情况。结果 观察组患者治疗总有效率95.00%显著高于对照组77.50%,差异有统计学意义(χ^(2)=12.265,P=0.002)。治疗后,观察组患者NIHSS评分、血清hs-CRP水平、血清TNF-α水平分别为(14.25±2.31)分、(3.78±0.56)mg/L、(0.28±0.04)ng/L,显著低于对照组,差异有统计学意义(t=7.471,15.596,10.982,P<0.05)。治疗后,观察组BI评分为(83.23±4.15)分,高于对照组,差异有统计学意义(t=8.316,P<0.05)。两组不良反应情况比较,差异无统计学意义(P>0.05)。结论针对大面积脑梗死患者,通过依达拉奉、奥拉西坦联合给药对疾病干预有突出的效用,促进患者神经系统的改善,此外也能降低炎症因子水平,使日常生活水平提升。

Objective To investigate the effect of edaravone combined with oxiracetam in clinical treatment on patients with massive cerebral infarction and its influence on neurological function.Methods A total of 80 patients with massive cerebral infarction admitted to Huanggang Central Hospital from January 2020 to April 2021 were randomly selected. According to the random number table method, they were divided into observation group and control group,with 40 cases in each group. The two groups were treated with basic intervention, the control group was treated with edaravone for 14 days, and the observation group was treated with edaravone combined with oxiracetam for 14 days.The clinical efficacy, changes in neurological function(NIHSS) and activities of daily living(BI), changes in serum inflammatory factors(hs-CRP, TNF-α) and adverse reactions were compared between the two groups.Results The total effective rate of patients in the observation group was 95.00%, which was significantly higher than 77.5% in the control group, and the difference was statistically significant(χ^(2)=12.265, P=0.002). After treatment, NIHSS score, serum hs-CRP level and serum TNF-α level of observation group were(14.25±2.31) points,(3.78±0.56) mg/L,(0.28±0.04) ng/L, respectively, which were significantly lower than in the control group, the difference was statistically significant(t=7.471, 15.596, 10.982, P<0.05). After treatment, the BI score of the observation group was(83.23±4.15)points, which was higher than that of the control group, and the difference was statistically significant(t=8.316, P<0.05). There was no statistically significant difference in the adverse reactions between the two groups(P>0.05).Conclusion For patients with large-area cerebral infarction, the combined administration of edaravone and oxiracetam has a prominent effect on disease intervention, can promote the improvement of the patient’s nervous system, and can also reduce the level of inflammatory factors, so as to improve the standard of daily life.